[1]郭晓燕,毕蓉蓉,张晔敏,等.活血化瘀祛痰法对野百合碱诱导的肺动脉高压大鼠肺血管重构的影响[J].陕西中医,2023,(1):3-6.[doi:DOI:10.3969/j.issn.1000-7369.2023.01.001]
　GUO Xiaoyan,BI Rongrong,ZHANG Yemin,et al.Effects of the method of promoting blood circulation and removing blood stasis and removing phlegm on pulmonary vascular remodeling in MCT-induced pulmonary hypertension rats[J].,2023,(1):3-6.[doi:DOI:10.3969/j.issn.1000-7369.2023.01.001]
点击复制

活血化瘀祛痰法对野百合碱诱导的肺动脉高压大鼠肺血管重构的影响

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年1期
页码:
3-6
栏目:
基础研究
出版日期:
2023-01-05

文章信息/Info

Title:
Effects of the method of promoting blood circulation and removing blood stasis and removing phlegm on pulmonary vascular remodeling in MCT-induced pulmonary hypertension rats
作者:
郭晓燕; 毕蓉蓉; 张晔敏; 陆城华
(上海中医药大学附属龙华医院,上海 200032)
Author(s):
GUO Xiaoyan; BI Rongrong; ZHANG Yemin; LU Chenghua
(Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China)
关键词:
肺动脉高压;  肺血管重构;  活血化瘀祛痰法;  野百合碱;  肺动脉平滑肌细胞;  Rho信号通路
Keywords:
Pulmonary hypertension;  Pulmonary vascular remodeling;  Promoting blood circulation and removing blood stasis and removing phlegm;  Monocrotaline;  Pulmonary artery smooth muscle cell;  Rho signaling pathway
分类号:
R 543.2
DOI:
DOI:10.3969/j.issn.1000-7369.2023.01.001
文献标志码:
A
摘要:
目的:观察活血化瘀祛痰法对野百合碱(MCT)诱导的肺动脉高压大鼠的影响,探讨其作用机制。方法:SD大鼠60只随机分为假手术组、模型组、中药复方组、法舒地尔组。采用MCT腹腔注射诱导肺动脉高压大鼠模型。观察大鼠一般状态,采用生物信号采集系统测定肺动脉压力,HE染色观察肺血管病理形态变化,Western blot法检测肺动脉组织ROCKⅠ、ROCKⅡ蛋白表达。结果:与假手术组比较,模型组右心肥大指数(RVHI)、肺动脉压力、肺血管增殖程度高于假手术组(P<0.05或P<0.01),中药复方组、法舒地尔组大鼠RVHI、肺动脉压力、肺血管壁厚度均低于模型组(P<0.05或P<0.01)。模型组ROCKⅠ、ROCKⅡ水平均较假手术组升高(P<0.05或P<0.01); 中药复方组、法舒地尔组ROCKⅠ、ROCKⅡ水平低于模型组(P<0.05或P<0.01); 中药复方组与法舒地尔组比较,差异无统计学意义(P>0.05)。结论:活血化瘀祛痰法对MCT诱导的肺动脉高压具有一定疗效,可降低肺动脉压力、改善肺血管重构,其机制与调节Rho激酶信号通路有关。
Abstract:
Objective:To observe the effect of the method of promoting blood circulation and removing blood stasis and removing phlegm on MCT-induced pulmonary hypertension,and to explore its mechanism.Methods:Sixty SD rats were randomly divided into sham operated group,model group,traditional Chinese medicine compound group and Fasudil group.A rat model of pulmonary arterial hypertension induced by monocrotaline.The general state of the rats was observed,pulmonary artery pressure was measured by the biological signal acquisition system,the pathological changes of the pulmonary blood vessels were observed by HE staining,and the protein expressions of ROCKⅠ and ROCKⅡ in the pulmonary artery tissue were detected by Western blot.Results:The degree of RVHI,pulmonary artery pressure,and pulmonary vascular WT in the model group were higher than those in the sham operated group(P<0.05 or P<0.01).The RVHI,pulmonary artery pressure,and pulmonary vascular WT in the traditional Chinese medicine compound group and Fasudil group were lower than those in the model group(P<0.05 or P<0.01).The levels of ROCKⅠ and ROCKⅡ in the model group were higher than those in the sham operation group(P<0.05 or P<0.01).The levels of ROCKⅠ and ROCKⅡ in the Chinese medicine compound group and Fasudil group were lower than those in the model group(P<0.05 or P<0.01).There was no significant difference compared with the Fasudil group and the Chinese medicine compound group(P>0.05).Conclusion:The method of promoting blood circulation and removing blood stasis and removing phlegm has a certain effect on MCT-induced pulmonary hypertension.It can reduce pulmonary artery pressure and improve pulmonary vascular remodeling,which is related to the regulation of Rho kinase signaling pathway.

参考文献/References:

[1] Luna-Lopez R,Ruiz MA.Pulmonary arterial hypertension[J].Med Clin-Barcelona,2022,158(12):622-629.
[2] Thenappan T,Shah SJ,Rich S,et al.A USA-based registry for pulmonary arterial hypertension:1982-2006[J].Eur Respir J,2007,30(6):1103-1110.
[3] 陈雨思,李 江.肺动脉高压靶向药物治疗现状和展望[J].中国临床新医学,2020,13(9):852-858.
[4] 王 瑞,武 云.肺动脉高压靶向药物治疗的研究进展[J].医学综述,2022,28(9):1776-1783.
[5] Mehari A.Trends in pulmonary hypertension mortality and morbidity[J].Pulm Med,2014,15(1):105864.
[6] 王 蕊,尚粉青,叶玉兰,等.KLF2在肺动脉高压大鼠肺组织中的表达及机制探讨[J].陕西医学杂志,2020,49(8):919-922.
[7] Rajagopal S,Yu YA.The pathobiology of pulmonary arterial hypertension[J].Cardiol Clin,2022,40(1):1-12.
[8] 赵文豪,金妮娜,伏 巧,等.中医药治疗肺动脉高压的研究进展[J].实用心脑肺血管病杂志,2022,30(5):80-83.
[9] 康睿男,李宜珊,张舒婷,等.中药在防治肺动脉高压中的作用及其研究进展[J].临床与病理杂志,2019,39(8):1790-1798.
[10] 吴 莹,韦 祎.中西医结合治疗慢性肺源性心脏病急性加重期56例[J].中国实验方剂学杂志,2012,18(23):316-319.
[11] 孙 波,刘文利.右心导管测定大鼠肺动脉压的实验方法[J].中国医学科学院学报,1984,6(6):465-467.
[12] 徐 欣,曲妮妮.基于现代文献研究肺动脉高压中医证型分布规律[J].河南中医,2019,39(2):245-249.
[13] 翟佳滨,吴晓锋,于笑艳,等.原发性肺动脉高压症中医辨治体会[J].中医杂志,2015,56(6):524-525.
[14] 杨 敏,李 慧,朱博文,等.川芎嗪抑制血管重塑的研究进展[J].中国中西医结合杂志,2018,38(3):379-383.
[15] 周 鑫,孙晓莹.中药单体川芎嗪在疾病治疗中的应用与机制研究进展[J].陕西中医,2022,43(4):541-544.
[16] 任周新,余海滨,梅晓峰,等.TGF-β1/BMP-4诱导肺动脉血管平滑肌细胞增殖及橙皮素、芍药苷的干预[J].中华中医药学刊,2018,36(6):1339-1342.
[17] Sun XJ,Tao MJ,Deng WL,et al.Effect of angelica solution on chronic hypoxic pulmonary hypertension in rats[J].Chin Pediatr Emerg Med,2011,18(3):249-251.
[18] 李 聪,赵 坤,张景良,等.黄芪多糖对野百合碱诱导的肺动脉高压大鼠肺动脉血管的保护作用及其机制[J].吉林大学学报:医学版,2021,47(6):1371-1379.
[19] 赵方允.野百合碱诱导大鼠肺动脉高压动物模型的制备[J].现代药物与临床,2021,36(10):2004-2007.
[20] 刘 云,孙增先.肺动脉高压血管重构信号机制研究进展[J].国际呼吸杂志,2022,42(7):507-512.
[21] 韩佳寅,易 艳,梁爱华,等.Rho/ROCK信号通路研究进展[J].药学学报,2016,51(6):853-859.

相似文献/References:

[1]王培东.血府逐瘀汤治疗慢性阻塞性肺疾病急性加重期合并肺动脉高压的临床观察[J].陕西中医,2017,(06):701.
[2]丁国瑞,贾壮壮,赵铎.三七总皂苷通过调控ERK/mTOR信号通路对肺动脉高压大鼠氧化应激水平的影响[J].陕西中医,2025,46(10):1312.[doi:DOI:10.3969/j.issn.1000-7369.2025.10.003]
　DING Guorui,JIA Zhuangzhuang,ZHAO Duo.Effects of panax notoginseng total saponins on oxidative stress levels in pulmonary hypertension rats by regulating the ERK/mTOR signaling pathway[J].,2025,46(1):1312.[doi:DOI:10.3969/j.issn.1000-7369.2025.10.003]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金青年基金资助项目(81302922); 上海市自然科学基金资助项目(19ZR1457900); 龙华医院科技创新项目
更新日期/Last Update: 2022-12-28